Carbon monoxide-releasing molecules triggered by physiological stimuli

A compound comprising a cyclopentenone moiety and a reactive moiety, wherein the compound has a structure according to Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is the reactive moiety, which is selected from the group consisting of —S(O)2R14, —S(O)R14, —SR14, —SeR13, —OS(O)2R14, —OR15, —OP(O)(OR15)2, —OC(O)R16, —OC(O)N(R17)2, and —N+(R17)3;
• R1 and R4 are independently selected from the group consisting of C1-8 alkyl, C3-8 cycloalkyl, C6-10 aryl, 3- to 8-membered heterocyclyl, 5- to 12-membered heteroaryl, —C(O)OR8, and hydrogen;
• R2 and R3 are taken together to form a fused tricyclic moiety or a fused bicyclic moiety, or
• R2 and R3 are independently selected from the group consisting of hydrogen, C1-8 alkyl, C3-8 cycloalkyl, C6-10 aryl, 3- to 8-membered heterocyclyl, 5- to 12-membered heteroaryl, and —C(O)OR8;
• R5 is selected from the group consisting of hydrogen, C1-8 alkyl, —CN, —C(O)OR9, —C(O)R10, —C(O)N(R11)2, and a targeting moiety;
• R6 is selected from the group consisting of —S(O)2R12, —S(O)R12, C1-8 alkyl, —CN, —C(O)OR9, —C(O)R10, —CH(OR10)2, —CH(SR10)2, —C(O)N(R11)2, and hydrogen;
• R7 is selected from the group consisting of hydrogen, C1-8 alkyl, —CN, —C(O)OR9, —C(O)R10, —CH(OR10)2, —CH(SR10)2, —C(O)N(R11)2, —S(O)R12, and —S(O)2R12;
• R8 is selected from the group consisting of hydrogen and C1-6 alkyl;
• each R9, R10, R11, and R12 is independently selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 acyl, C6-10 aryl, and a targeting moiety;
• each R13, R15, R16, and R17 is independently selected from the group consisting of C1-8 alkyl, C3-8 cycloalkyl, C6-10 aryl, and 5- to 12-membered heteroaryl;
• R14 is independently selected from the group consisting of C6-10 aryl, C1-8 alkyl, C3-8 cycloalkyl, and 5- to 12-membered heteroaryl;
• in R6 or R7, one of R9, R10, R11, and R12 is optionally taken together with one of R13, R14, R15, R16, and R17 to form a monocyclic moiety;
• each of R1-R17 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, C1-4 alkyl,
• C1-4 haloalkyl, —CN, —NO2, —ORa, —C(O)Rb, —C(O)ORa, —OC(O)Rb,
• —N(Ra)2, —NRaC(O)Rb, —C(O)N(Ra)2, —S(O)Rb, —S(O)2Rb, —S(O)2ORa,
• —S(O)2N(Ra)2, and —NRaS(O)2Rb;
• each Ra is independently selected from the group consisting of hydrogen, C1-4 alkyl, a solubilizing moiety, and a targeting moiety;
• and
• each Rb is independently selected from the group consisting of C1-4 alkyl, a solubilizing moiety, and a targeting moiety,
• wherein exposure of the compound to physiological conditions results in elimination of the reactive moiety and release of carbon monoxide.